[New therapeutic strategies, a chimeric fusion protein inhibits allergic reactivity].
Allergic responses are strongly associated with Th2-type immune responses, and modulation of the skewed Th2 response toward a more balanced response is the major goal of allergen immunotherapy (IT) in allergic disorders. To achieve this goal, several approaches have been tested. The author found that human gamma-allergen fusion protein achieve an inhibitory effect in an allergen-specific fashion while preserving the immunogenicity of the allergen component. Therefore, the authors constructed and developed a human-cat chimeric fusion protein composed of the human Fcgammal and the cat allergen Fel d1 (Felis domesticus) for cat allergen-specific IT. This article summarizes the therapeutic features and potential of this novel fusion protein for allergic IT.
Terada
Tetsuya
T
Department of Otolaryngology, Head and Neck Surgery, Rakuwakai Otowa Hospital.
D000818:Animals; D006967:Hypersensitivity / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D011993:Recombinant Fusion Proteins